(050) RESULTS FROM A PATIENT SURVEY EXPLORING THE EFFECTS OF FLIBANSERIN IN WOMEN WITH HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) BASED ON TREATMENT DURATION
Notice bibliographique
Résumé
Abstract Introduction Flibanserin is approved in the US to treat premenopausal women and in Canada for pre- and naturally postmenopausal women ≤60 years with acquired, generalized HSDD. Improvement in symptoms can emerge as early as 4 weeks after starting flibanserin but may take up to 8 weeks of daily use. There is limited real-world data exploring patient response to flibanserin based on treatment duration. Objective Analyze results from a patient survey to explore the effects of flibanserin based on treatment duration Methods Women aged ≥18 years with HSDD prescribed flibanserin via a telehealth platform were invited to participate. Invitational emails containing a secure study link, generated via the platform, were sent 60 days after an initial or renewed flibanserin prescription during the study period (August 1, 2022, to September 30, 2023). The first question screened for current flibanserin use. Women who had discontinued treatment exited the survey. Questions captured changes in HSDD symptoms, partner relationships, weight, sleep, and mood since starting flibanserin. Five multiple-choice response options accompanied each question. A response of “improved a lot” or “improved a little” was categorized as “Benefit”, and a response of “no change,” “worsened a little,” or “worsened a lot” was categorized as “No Benefit”. Results were analyzed descriptively based on treatment duration. Results Invitational emails were sent to 17,113 women. Of 638 women who accessed the link, 199 had discontinued flibanserin and exited the survey, and 439 completed the survey (mean age 40 [range 21-66] years). Duration of therapy was <1 month, 1-2 months, and >2 months in 44, 231, and 164 women, respectively. The percentage of women reporting benefits in HSDD symptoms and partner relationships consistently increased with longer treatment. For weight loss and mood, there was a trend of more women experiencing benefit with continued use. For those who experienced improved sleep quality, the improvement began early (<1 month); the percentage of respondents experiencing benefit or lack of benefit in sleep did not change over prolonged use. Conclusions Daily flibanserin use may increase interest in sexual activity and improve partner relationships in certain women. These improvements may emerge as early as one month following treatment initiation. However, consistent with previous findings, some women may need longer treatment durations. As expected, effects on weight and mood may take longer to emerge. The impact on sleep quality may be apparent early in treatment and remain consistent with continued use. Disclosure Yes, this is sponsored by industry/sponsor: Sprout Pharmaceuticals, Inc Clarification: Industry initiated, executed and funded study Any of the authors act as a consultant, employee or shareholder of an industry for: Sprout Pharmaceuticals, Inc.
Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.
Comment cette classification a été obtenuedéplier
Prédiction distillée sur la base complète
Imitation des enseignantsNi prévalence calibrée, ni vérité terrain. Validation humaine à venir. Apprise à partir de 10 348 étiquettes directes de Codex et de 10 348 étiquettes directes de Gemma. Le mode candidate est l'union des têtes enseignantes seuillées; le consensus est leur intersection. Ces sorties portent le statut machine_predicted_unvalidated et ne sont ni des étiquettes humaines ni des étiquettes directes de modèles de pointe.
Scores Codex et Gemma par catégorie
| Catégorie | Codex | Gemma |
|---|---|---|
| Métarecherche | 0,001 | 0,001 |
| Méta-épidémiologie (sens strict) | 0,000 | 0,000 |
| Méta-épidémiologie (sens large) | 0,001 | 0,000 |
| Bibliométrie | 0,000 | 0,001 |
| Études des sciences et des technologies | 0,000 | 0,000 |
| Communication savante | 0,000 | 0,000 |
| Science ouverte | 0,000 | 0,000 |
| Intégrité de la recherche | 0,000 | 0,000 |
| Charge utile insuffisante (le modèle a refusé de juger) | 0,000 | 0,000 |
Scores machine (provisoires)
Les deux têtes enseignantes du modèle étudiant, lues sur ce travail. Un score ordonne la base pour la relecture; il n'affirme jamais une catégorie, et le statut de validation accompagne chaque rangée tel quel.
Scores de référence d'un modèle non mature (critères de maturité non atteints, 7 itérations). Un score ordonne; il n'affirme jamais une catégorie.
score_only:v0-immature-baseline · tel quel depuis la passe de notation : score_only signifie que le nombre peut ordonner les travaux, et qu'aucune étiquette de catégorie n'en découleClassification
machine, non validéePrédiction automatique; un appel candidat d’une seule tête enseignante, pas un consensus.
Le détail, modèle par modèle et score par score, se trouve en fin de page sous « Comment cette classification a été obtenue ».